ライフサイエンスコーパス: thyroxine

1 mide derivatives of thyroxine or deiodinated thyroxine.

2 ormation of impurities in thermally stressed thyroxine.

3 ring the biosynthesis of the thyroid hormone thyroxine.

4 ssociated with both free thyroxine and total thyroxine.

5 total antioxidant power was not affected by thyroxine.

6 ocesses could be inhibited by probucol and L-thyroxine.

7 the two binding sites for the natural ligand thyroxine.

8 y measurements of serum thyrotropin and free thyroxine.

9 vasopressin and either triiodothyronine or L-thyroxine.

10 vasopressin and either triiodothyronine or l-thyroxine.

11 ve became hypothyroid and required long-term thyroxine.

12 , estrogen therapy may increase the need for thyroxine.

13 eased the responsiveness of immature rats to thyroxine.

14 cytes, with triiodothyronine (100 pmol/L) or thyroxine (100 nmol/L).

15 ne, tetramethylrosamine, fluoride, dopamine, thyroxine, 2,4-dinitrotoluene) and activated gene expres

16 Thyroid stimulating hormone, free thyroxine, 25-hydroxy vitamin D3, active smoking status

17 tly increased uptake of triiodothyronine and thyroxine (4.1- and 4.3-fold, respectively), which was a

18 much longer half-life of D3 (12 h) than the thyroxine activating members of the selenodeiodinase fam

19 ated reduction of the type 2 deiodinase, the thyroxine-activating enzyme, and both effects are revers

20 s alone and steroids plus triiodothyronine/l-thyroxine also significantly reduced prolonged graft dys

21 mong these women, associations between total thyroxine and concurrent 1996 TCDD were slightly weaker

22 y that resulted in low circulating levels of thyroxine and IGF-1.

23 tube recognition complexes for riboflavin, L-thyroxine and oestradiol.

24 vidence that transthyretin, a transporter of thyroxine and retinol, is aggregated in preeclampsia and

25 blood and cerebrospinal fluid transporter of thyroxine and retinol.

26 , one of which defines the binding sites for thyroxine and small-molecule amyloidogenesis inhibitors.

27 The concentration of thyroxine and the free thyroxine index were higher in th

28 R exists as a tetramer and binds the hormone thyroxine and the retinol-binding protein-vitamin A comp

29 rameric protein involved in the transport of thyroxine and the vitamin A-retinol-binding protein comp

30 nction in mice, resulting in increased serum thyroxine and thyroidal radioiodide uptake.

31 with normal thyroid function, the serum free thyroxine and thyrotropin concentrations did not change,

32 ypothyroidism had similar increases in serum thyroxine and thyroxine-binding globulin concentrations

33 ns were negatively associated with both free thyroxine and total thyroxine.

34 antly associated with greater total and free thyroxine and total triiodothyronine among women and wit

35 pacity for rapid inactivation of circulating thyroxine and triiodothyronine in patients with hemangio

36 stem tone, and circulating concentrations of thyroxine and triiodothyronine returned to pre-weight-lo

37 hormone thyrotropin and the thyroid hormones thyroxine and triiodothyronine) are sometimes used as in

38 on, including those for the thyroid hormones thyroxine and triiodothyronine, are among the clinical p

39 t serum protein responsible for transporting thyroxine and vitamin A.

40 TSH (thyroid-stimulating hormone), FT4 (free thyroxine) and gait, without known thyroid disease or de

41 ) for statins, 1.40 (95% CI: 1.02, 1.92) for thyroxine, and 1.53 (95% CI: 1.04, 2.24) for insulin.

42 One group of HLE B-3 cells was treated with thyroxine, and another group was not.

43 s well as thyroid-stimulating hormone, total thyroxine, and free thyroxine, were measured in serum sa

44 centrations of plasma tri-iodothyronine, low thyroxine, and normal range or slightly decreased concen

45 10 case-control pairs were assessed for free thyroxine, and sera of 948 case-control pairs were asses

46 ating hormone, thyroglobulin, total and free thyroxine, and total and free triiodothyronine.

47 ne and circulating concentrations of leptin, thyroxine, and triiodothyronine act coordinately to favo

48 a on the adverse effects of broader use of L-thyroxine are sparse.

49 vels of transthyretin, a carrier protein for thyroxine, are elevated.

50 This approach was tested using L-thyroxine as a model analyte.

51 that the TTR amyloid is incapable of binding thyroxine as monitored by either isothermal calorimetry

52 e stable isotopic thyroid hormone (13)C(6)-L-thyroxine as the label of which the binding to rTTR is i

53 s, resulting in the formation of deiodinated thyroxines, as well as acetic acid, benzoic acid, formal

54 in (Tg) T cell epitope p2549-2560 containing thyroxine at position 2553 (T4p2553) induces thyroiditis

55 ted six promoters, CMV, EF1alpha, PGK, apoE, thyroxine binding globulin (TBG), and cytochrome P450 2E

56 coagulation factor V, adiponectin, CRP, and thyroxine binding globulin, respectively.

57 coagulation factor V, adiponectin, CRP, and thyroxine binding globulin, respectively.

58 , adiponectin, C-reactive protein (CRP), and thyroxine binding globulin.

59 tion in vitro via an interaction between the thyroxine binding pocket of the TTR tetramer and Abeta r

60 minophenyl substructure to bind to the inner thyroxine binding pocket of TTR.

61 t only utilizes the outer portion of the two thyroxine binding pockets to bind to and inhibit TTR amy

62 o complement the unused inner portion of the thyroxine binding pockets.

63 units whose quaternary interface defines the thyroxine binding site also dramatically increases the b

64 Binding of small molecule ligands within the thyroxine binding site of TTR can stabilize the tetramer

65 ivity enables these inhibitors to occupy the thyroxine binding site(s) in a complex biological fluid

66 When bound in the thyroxine binding site, most of the aryl sulfonyl fluori

67 ter than the hydrolysis reaction outside the thyroxine binding site.

68 teract, albeit weakly, with the preferential thyroxine binding site.

69 Occupancy of only one of the two thyroxine binding sites is sufficient to inhibit tetrame

70 Although revealing the ability of the two thyroxine binding sites of TTR to discriminate between d

71 tion state by small molecule binding to both thyroxine binding sites raises the kinetic barrier of te

72 pposing subunits on the periphery of the two thyroxine binding sites.

73 of TTR by specifically interacting with its thyroxine binding sites.

74 yl known to have high affinity for the inner thyroxine binding subsite of transthyretin (TTR) was con

75 +/-19 nmol per liter, P<0.001) and the serum thyroxine-binding globulin concentration had increased f

76 had similar increases in serum thyroxine and thyroxine-binding globulin concentrations during estroge

77 olely to estrogen-induced increases in serum thyroxine-binding globulin or whether other factors are

78 injecting adeno-associated virus containing thyroxine-binding globulin promoter-driven causes recomb

79 thyroxine, free thyroxine, thyrotropin, and thyroxine-binding globulin were measured.

80 and ~200 nM) to the two normally unoccupied thyroxine-binding sites of the tetramer, and kinetically

81 to deliver Tg to its site of iodination for thyroxine biosynthesis.

82 ghly preferential binding of resveratrol and thyroxine, both characterized by negative binding cooper

83 the relationship between 1976 TCDD and total thyroxine but drove the association with 1996 TCDD to th

84 evel of the predominant thyroid hormone free thyroxine, but not the minimal isoform of triiodothyroni

85 sruption due to high affinity-binding to the thyroxine-carrying protein, transthyretin.

86 xinemia, characterized by low levels of free thyroxine coexisting with reference thyrotropin levels,

87 uring estrogen therapy, but their serum free thyroxine concentration decreased from 1.7+/-0.4 ng per

88 , whereas at 12 weeks the mean (+/-SD) serum thyroxine concentration had increased from 8.0+/-0.9 mic

89 % CI: 0.12, 1.51) increase in maternal total thyroxine concentrations (TT4), respectively.

90 o decreased circulating triiodothyronine and thyroxine concentrations secondary to reduced mRNA expre

91 oiding toxicity are based on the circulating thyroxine concentrations, the presence of thyroid stimul

92 evel of 5.0 to 19.96 mIU/l with normal total thyroxine concentrations.

93 id not affect blood lymphocyte or serum free thyroxine concentrations.

94 ngeners were negatively associated with free thyroxine concentrations.

95 18-30 microM included L-thyroxine (L-T4), D-thyroxine (D-T4), 3,3', 5,5'-tetraiodothyroacetic acid (

96 lpha), collagen I and III transcription, and thyroxine decreased cyclin-dependent kinase inhibitor 2A

97 ipation, which improved after treatment with thyroxine, despite normal concentrations of circulating

98 ough it is reasonable to expect a need for a thyroxine dose increase with some antiepileptic drugs, t

99 In women with hypothyroidism treated with thyroxine, estrogen therapy may increase the need for th

100 tic compounds, including L-triiodothyronine, thyroxine, estrone, p-nitrophenol, 2-naphthylamine, and

101 A continuous infusion of 4 mug/kg per day thyroxine for 42 days can safely correct transient hypot

102 injected either with growth hormone (GH) or thyroxine for a 6-wk period to see whether this interven

103 ored in adults part of the responsiveness to thyroxine found in immature rats and (b) arrested the no

104 Thyroxine, free thyroxine index, and thyroid-stimulating

105 981) and 1996 (n = 260), and levels of total thyroxine, free thyroxine, free triiodothyronine, and th

106 On each occasion, serum thyroxine, free thyroxine, thyrotropin, and thyroxine-bi

107 = 260), and levels of total thyroxine, free thyroxine, free triiodothyronine, and thyroid-stimulatin

108 otal thyroxine, total triiodothyronine, free thyroxine, free triiodothyronine, parathyroid hormone, p

109 peech), biochemical (subnormal ratio of free thyroxine:free tri-iodothyronine [T3], low concentration

110 0.70; 95% CI: -1.06, -0.34], decreasing free thyroxine (fT4) (beta = -0.053; 95% CI: -0.092, -0.013),

111 cted thyroid stimulating hormone (TSH), free thyroxine (FT4) and thyroid peroxidase antibody (TPOAb)

112 tside the reference range and levels of free thyroxine (FT4) and triiodothyronine (T3) within the ref

113 hyroidism as TSH 4.5 to 19.9 mIU/L with free thyroxine (fT4) levels within reference range.

114 ars with thyroid-stimulating hormone or free thyroxine (FT4) measurements and clinical follow-up were

115 s of thyroid-stimulating hormone (TSH), free thyroxine (FT4), and thyroglobulin, vary widely due to v

116 Maternal serum levels of free thyroxine (FT4), thyroid-stimulating hormone (TSH), and

117 le thyroid traits thyrotropin (TSH) and free thyroxine (FT4), we analyse whole-genome sequence data f

118 TCEP had additional overall effects on free thyroxine (FT4), whereas TDCIPP also influenced total th

119 lso positively associated with maternal free thyroxine (FT4).

120 unction tests (serum thyrotropin [TSH], free thyroxine [fT4], and thyroid peroxidase [TPO] antibodies

121 by solid phase synthesis with immobilised L-thyroxine, glucosamine, fumonisin B2 or biotin as templa

122 ithin the ER with no detectable synthesis of thyroxine, had persistent exposure of free cysteine thio

123 thyroid-stimulating hormone; treatment with thyroxine has been initiated in one patient.

124 growth factor, insulin-like growth factor-1, thyroxine, hepatocyte growth factor, and bone morphogene

125 s (CTL) and hypothyroid rats replaced with L-thyroxine (HT+T).

126 Replacement treatment exists in the form of thyroxine, hydrocortisone, sex steroids, growth hormone,

127 ausal women with hypothyroidism treated with thyroxine, I assessed thyroid function before they start

128 tly shown to reduce levels of free and total thyroxine in experimental animal studies, the direction

129 age-associated decrease in responsiveness to thyroxine in immature rats.

130 antiepileptic drugs, the effect of excessive thyroxine in lowering seizure threshold should also be c

131 converting enzyme (ACE), and measuring serum thyroxine in mice given anti-TGFbeta1 or the ACE inhibit

132 hods when used for the determination of free thyroxine in serum samples.

133 of the tumor and high circulating levels of thyroxine in the absence of exogenous hormone.

134 e was derived for the thermal degradation of thyroxine in the solid state, using data obtained from u

135 ses for 3 medications (statins, insulin, and thyroxine) in relation to 3 outcomes (retinal detachment

136 i-iodothyronine uptake (T3 uptake), and free thyroxine index (FTI) were measured.

137 ine, triiodothyronine resin uptake, and free thyroxine index (FTI), were determined before initiation

138 The concentration of thyroxine and the free thyroxine index were higher in the ISP56 group, and the

139 Thyroxine, free thyroxine index, and thyroid-stimulating hormone at 6 mo

140 Response curves to injected thyroxine indicated that immature rats were three times

141 Therefore, thyroxine-induced fluctuations in antioxidant levels are

142 However, binding of RBP, but not thyroxine, inhibited subsequent fibrillogenesis.

143 reased levels of free triiodothyronine, free thyroxine, insulin-like growth factor 1, insulin-like gr

144 Originating in the thyroid, the prohormone thyroxine is converted to triiodothyronine, which is ess

145 L-thyroxine (L-T4) malabsorption is a potential concern in

146 ith IC(50) values of 18-30 microM included L-thyroxine (L-T4), D-thyroxine (D-T4), 3,3', 5,5'-tetraio

147 triiodothyronine was detected, although the thyroxine level decreased in patients receiving eprotiro

148 in 1976 was inversely associated with total thyroxine level in 1996 but not in 2008.

149 pin level, 4.60 to 19.99 mIU per liter; free thyroxine level within the reference range).

150 ontrols, the knock-outs had markedly reduced thyroxine levels ( approximately 50-80%) and profoundly

151 ncreased in a linear manner with higher free thyroxine levels (hazard ratio, 2.41; confidence interva

152 Thyroxine levels and urinary free cortisol levels were p

153 are hypothyroid, and normalization of serum thyroxine levels does not reduce TEC H/P.

154 of C2GnT3 altered behavior linked to reduced thyroxine levels in circulation.

155 Free thyroxine levels in middle-aged and elderly subjects wer

156 ol retinol-binding protein, vitamin A, and L-thyroxine levels in plasma and have the potential to mod

157 vated free triiodothyronine and lowered free thyroxine levels in the blood.

158 y cultured thyroid cells and increased serum thyroxine levels in TSH-suppressed rats in vivo.

159 Moreover, intrathyroid thyroxine levels of Slc30a10 single knockouts were lower

160 Higher free thyroxine levels were associated with lower cumulative n

161 inished weight gain and reduced plasma total thyroxine levels were found in both groups compared with

162 Free thyroxine levels were positively associated with high co

163 H <0.45 mIU/L, the last two with normal free thyroxine levels.

164 who have abnormal TSH levels and normal free thyroxine levels.

165 rmone, thyroid-stimulating hormone, and free thyroxine levels.

166 , may have enduring impacts on women's total thyroxine levels.

167 Maternal hypothyroxinemia (free thyroxine </=10th percentile, normal thyroid-stimulating

168 Thyroxine modifies expressions of KSPG synthesis and car

169 uggests mechanisms for the inadequacies of l-thyroxine monotherapy and highlights the possible role f

170 Thereafter, l-thyroxine monotherapy at doses to normalize the serum TS

171 The last sentence of the section titled "L-Thyroxine Monotherapy Fails to Restore All Markers of Hy

172 has brought into question the inability of l-thyroxine monotherapy to universally normalize serum T3

173 on provided a physiologic means to justify l-thyroxine monotherapy, obviating concerns about inconsis

174 s, retinol-binding protein, vitamin A, and L-thyroxine, notably influenced transthyretin amyloidogeni

175 tic parameters, such as Km, Vmax and Ki (for thyroxine), obtained by electrospray mass spectrometry a

176 th hypothyroidism that is being treated with thyroxine often need higher doses when they are pregnant

177 ality in a cohort of 1191 individuals not on thyroxine or antithyroid medication.

178 oxyacetamide, or oxoacetamide derivatives of thyroxine or deiodinated thyroxine.

179 Binding of the natural ligands thyroxine or retinol-binding protein (RBP) by Ser52Pro v

180 significant competition for resveratrol and thyroxine preferential binding sites and lacked the abil

181 ons of polyphenols with both resveratrol and thyroxine preferential binding sites, by using resveratr

182 by elevated thyroid manganese, which blocks thyroxine production.

183 variate analysis, age, treatment group, free thyroxine, protein, and magnesium levels were associated

184 When thyroxine recipients were excluded, the HRs for particip

185 Thyroxine replacement therapy is highly effective and sa

186 U per milliliter in 7 of the 18 women in the thyroxine-replacement group and to more than 1 microU pe

187 h hypothyroidism included 18 women receiving thyroxine-replacement therapy and 7 women receiving thyr

188 ies formed between tetrameric transthyretin, thyroxine, retinol-binding protein, and retinol.

189 d the selection of conditions for removal of thyroxine's free fraction from samples without significa

190 Thyrotropin and free thyroxine should be measured and, when the latter is nor

191 tion factor A (TFAM) protein expression, and thyroxine stimulated complex II/IV activity.

192 ypothyroidism was defined by an above normal thyroxine-stimulating hormone concentration or by the ne

193 products" like the synthetic thyroid hormone thyroxine, strict regulations enforce a detailed chemica

194 but those treated with replacement doses of thyroxine survived more than 8 weeks.

195 ized interaction between the thyroid hormone thyroxine (T(4)) and the proinflammatory cytokine macrop

196 on of the contrast agent were collected, and thyroxine (T(4)) and thyroid-stimulating hormone (TSH) l

197 Thyroid hormone thyroxine (T(4)) and tri-iodothyronine (T(3)) production

198 The thyroid hormones thyroxine (T(4)) and triiodothyronine (T(3)) play key ro

199 emical thyroidectomy on the one hand, and by thyroxine (T(4)) and triiodothyronine (T(3)) replacement

200 ear thyroid hormone receptor TRbeta1 (TR), L-thyroxine (T(4)) causes activation and nuclear transloca

201 transiently tetramerized by the locally high thyroxine (T(4)) concentration, chaperoning it out into

202 al thyroidectomy or after discontinuation of thyroxine (T(4)) in patients with thyroid cancer.

203 Thyroxine (T(4)) is the predominant form of thyroid horm

204 L-Thyroxine (T(4)) nongenomically promotes association of

205 Mesothelioma cell lysates activate thyroxine (T(4)) to 3,5,3'-triiodothyronine with typical

206 at catalyze the conversion of the prohormone thyroxine (T(4)) to the active form of thyroid hormone,

207 ect of NT69L on blood glucose, cortisol, and thyroxine (T(4)) were all back to control levels after f

208 sitive method for the analysis of six THs, l-thyroxine (T(4)), 3,3',5-triiodo-l-thyronine (T(3)), 3,3

209 Thyroid-stimulating hormone (TSH), free thyroxine (T(4)), free triiodothyronine (T(3)), and lept

210 ples for measurement of thyrotropin and free thyroxine (T(4)).

211 um concentration of the thyroid hormone (TH) thyroxine (T(4)).

212 onine) with high affinity, and its precursor thyroxine (T(4), 3,5,3',5'-tetraiodo-l-thyronine) with l

213 ion of thyroid hormones triiodothyronine and thyroxine (T3/T4) can impact metabolism, body compositio

214 Serum thyroxine, T3, and thyroid-stimulating hormone (TSH) lev

215 3,5,3'-triiodothyronine (T3) and high serum thyroxine/T3 (T4/T3) ratio.

216 HFs whether TRH (30 nM), TSH (10 mU ml(-1)), thyroxine (T4) (100 nM), and triiodothyronine (T3) (100

217 sociated with a 2.6-mug/dL decrease in total thyroxine (T4) (95% CI: -4.7, -0.35).

218 asing log10 perchlorate and decreasing total thyroxine (T4) [regression coefficient (beta) = -0.70; 9

219 selenoenzyme that activates the pro-hormone thyroxine (T4) and supplies most of the 3,5,3'-triiodoth

220 luorododecanoic acid (PFDoDA) had lower free thyroxine (T4) and total T4 levels.

221 tion, circulating levels of thyroid hormones thyroxine (T4) and triiodothyronine (T3) averaged 46.9 a

222 yroid, or thyroglobulin), which contain both thyroxine (T4) and triiodothyronine (T3), were the first

223 Serum triiodothyronine (T3) and thyroxine (T4) concentrations were slightly elevated com

224 The displacement of l-thyroxine (T4) from binding sites on transthyretin (TTR)

225 e thyroid hormones triiodothyronine (T3) and thyroxine (T4) in aquatic wildlife exists despite the fa

226 Thyroxine (T4) injected in ovo on E9 induces precocious

227 4.00 mU or more per liter and a normal free thyroxine (T4) level (0.86 to 1.90 ng per deciliter [11

228 boxylate transporter 8 (MCT8) have low serum thyroxine (T4) levels that cannot be fully explained by

229 m 3,5,3'-triiodothyronine (T3) with normal l-thyroxine (T4) levels, is associated with malignancy.

230 We administered vehicle, thyroxine (T4) or metformin to neonatal rats post FAE an

231 hormones leptin, triiodothyrionine (T3), and thyroxine (T4) remain uncertain.

232 evidence suggests that the thyroid hormone L-thyroxine (T4) stimulates growth of cancer cells via a p

233 es the type 2 deiodinase (D2) that activates thyroxine (T4) to 3,3',5-triiodothyronine (T3), the disr

234 elenoenzymes that catalyze the conversion of thyroxine (T4) to 3,5,3'-triiodothyronine (T3) and 3,3',

235 (D2) activates thyroid hormone by converting thyroxine (T4) to 3,5,3'-triiodothyronine (T3).

236 perthyroidism was generated by addition of L-thyroxine (T4) to drinking water.

237 o2a and dio2b, responsible for conversion of thyroxine (T4) to T3.

238 est), the ratio of the circulating precursor thyroxine (T4) to the active form 3,5,3'-triiodothyronin

239 pe II iodothyronine deiodinase (D2) converts thyroxine (T4) to the active hormone 3,5,3'-triiodothyro

240 pe 2 deiodinase (D2) converts the prohormone thyroxine (T4) to the metabolically active molecule 3,5,

241 zymes, such as TH deiodinases, which convert thyroxine (T4) to the physiologically active TH, triiodo

242 DIO2 converts thyroxine (T4) to triiodothyronine (T3), which binds to

243 Serum TSH and free thyroxine (T4) were measured.

244 thyroid hormones (triiodothyronine (T3) and thyroxine (T4)), thyroid-stimulating hormone, thyroid pe

245 The thyroid hormones triiodothyronine (T3), thyroxine (T4), and thyrotropin (TSH) were measured in p

246 e examined through thyroid histology, plasma thyroxine (T4), and triiodothyronine (T3), and hepatic o

247 f the label by the natural thyroid hormone l-thyroxine (T4), as a model analyte, is demonstrated in w

248 Serum insulin, thyroxine (T4), corticosterone, and adipokines were meas

249 oped for the analysis of the thyroid hormone thyroxine (T4), inflammation biomarker C-reactive protei

250 Rats received placebo, 3.3-mg l-thyroxine (T4), or 20-mg T4 pellets (60-day release form

251 We also measured free thyroxine (T4), total T4, and thyroid-stimulating hormon

252 The thyroid gland synthesizes thyroxine (T4), which passes through the larval tadpole'

253 1 induced a dose-dependent increase in serum thyroxine (T4), with a maximum effect after 10 proportio

254 Assay specificity was improved by the use of thyroxine (T4)-binding globulin as a second ligand-bindi

255 PCR, we identified a class of genes encoding thyroxine (T4)-binding proteins (transthyretin, T4-bindi

256 Precocious thyroxine (T4)-induced increases in corneal thinning/tra

257 The TTR-binding activity was measured as thyroxine (T4)-like equivalents (T4-EQMeas).

258 ced to undergo metamorphosis via exposure to thyroxine (T4).

259 r levels of triiodothyronine (T3) and higher thyroxine (T4).

260 phytohaemagglutinin skin test, p < 0.0001), thyroxine (T4, p = 0.042), and glutathione (GSH, p = 0.0

261 eled T3 internal standard (T3-13C9), labeled thyroxine (T4-d5) is also added to serum samples in orde

262 ing vessels was increased 3-fold by either l-thyroxine (T4; 10(-7) mol/L) or 3,5,3'-triiodo-l-thyroni

263 membrane receptor, binds thyroid hormones (L-thyroxine, T4; 3,5,3'-triiodo-L-thyronine, T3) and is ov

264 Thyroxine (tetraiodothyronine [T4]), T3, and TSH levels

265 ure rats were three times more responsive to thyroxine than adult rats.

266 l compartment to a hypertrophic regimen with thyroxine, the cartilage discs underwent progressive dee

267 e 2 deiodinase (D2), an enzyme that converts thyroxine, the main form of thyroid hormone in the circu

268 In 10 patients receiving thyroxine, the mean retention of diagnostic (131)I after

269 mmune thyroiditis, of whom 56 were receiving thyroxine therapy.

270 of hypothyroidism, 11 of whom were receiving thyroxine therapy.

271 nd 7 women receiving thyrotropin-suppressive thyroxine therapy.

272 urrently reads "... for steady delivery of L-thyroxine").This has been corrected in the online versio

273 al thyroid hormone levels (thyrotropin, free thyroxine, thyroid peroxidase antibodies) were measured

274 On each occasion, serum thyroxine, free thyroxine, thyrotropin, and thyroxine-binding globulin w

275 time of 90 ms and allowed the amount of free thyroxine to be determined within 30 s after sample inje

276 thelial cell line, HLE B-3, was treated with thyroxine to determine whether this treatment increases

277 eiodinase (D2) that activates the prohormone thyroxine to the active hormone triiodothyronine, modify

278 activation by accelerating the conversion of thyroxine to triiodothyronine via type 2 deiodinase in m

279 ones (ie, thyroid-stimulating hormone, total thyroxine, total triiodothyronine, free thyroxine, free

280 The tetrameric thyroxine transport protein transthyretin (TTR) forms am

281 Transthyretin (TTR) is a thyroxine-transport protein found in the blood that has

282 ays of growth in a hyperoxic atmosphere, the thyroxine-treated cells were 20 times more viable than w

283 in the amount of lipid oxidation products in thyroxine-treated cells.

284 Thyroxine treatment alleviates hormone resistance in pat

285 A 100% increase in cardiolipin with thyroxine treatment may contribute to a decrease in reac

286 Thyroxine treatment reduced the amount of lipid oxidatio

287 As a result of thyroxine treatment, the phosphatidylcholine (PC)-to-sph

288 including thyroid-stimulating hormone (TSH), thyroxine, triiodothyronine resin uptake, and free thyro

289 compensate for thyroid dysfunction, as serum thyroxine/triiodothyronine and somatic growth were norma

290 d a 53% and 46% decline in circulating total thyroxine (TT4) and 3,5,3'-triiodothyronine (TT3), respe

291 of thyroid-stimulating hormone (TSH), total thyroxine (TT4), and PFAAs were measured during 2005-200

292 (FT4), whereas TDCIPP also influenced total thyroxine (TT4).

293 ips between thyroid hormones (total and free thyroxine [TT4 and FT4], total and free triiodothyronine

294 Binding of the natural ligand thyroxine was clearly observed, and a range of small mol

295 A maleimide-activated thyroxine was selected as the model analyte and site-spe

296 A heterogeneous assay for thyroxine was then developed by employing the geneticall

297 imulating hormone, total thyroxine, and free thyroxine, were measured in serum samples collected betw

298 of the thyroid hormones triiodothyronine and thyroxine, which are required for the development of the

299 hypothyroidism is replacement with synthetic thyroxine, which undergoes peripheral conversion to trii

300 ions of thyroid-stimulating hormone and free thyroxine with the outcomes were assessed through logist